ALC Stock Overview
Researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ALC from our risk checks.
Alcon Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 89.08 |
| 52 Week High | CHF 92.65 |
| 52 Week Low | CHF 69.44 |
| Beta | 0.70 |
| 11 Month Change | 1.96% |
| 3 Month Change | 6.95% |
| 1 Year Change | 8.49% |
| 33 Year Change | 26.25% |
| 5 Year Change | 46.37% |
| Change since IPO | 53.48% |
Recent News & Updates
Recent updates
Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)
May 14Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales
Oct 10Alcon: Lackluster Growth Given Its Valuation
Jul 26Alcon: The Steady Force Of 'Boring'
Jun 27Alcon reached $199M settlement with J&J Surgical Vision
Feb 13Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings
Feb 01Alcon a buy at Mizuho on 'eyecare dominance'
Dec 22Alcon Q3 2022 Earnings Preview
Nov 14Alcon: Looking To Break Downtrend Before Entry
Sep 04Alcon downgraded to hold at Societe Generale on macro headwinds
Aug 11Alcon: Revisiting The Investment Thesis
Jun 03The Recent Pullback Makes Alcon More Attractive
Mar 18Alcon: Good Quarterly Results, But It Is Still Expensive
Dec 22Looking At Alcon Through A Different Lens
Sep 11Alcon Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06Alcon to acquire U.S. commercialization rights to ophthalmic eye drops Simbrinza from Novartis
Apr 28Alcon: Global Leader In An Attractive End-Market
Dec 16Alcon Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 11Alcon Q3 2020 Earnings Preview
Nov 09Shareholder Returns
| ALC | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -0.04% | -0.8% | 0.04% |
| 1Y | 8.5% | -2.8% | 20.7% |
Return vs Industry: ALC exceeded the US Medical Equipment industry which returned -1.3% over the past year.
Return vs Market: ALC underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| ALC volatility | |
|---|---|
| ALC Average Weekly Movement | 3.8% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ALC has not had significant price volatility in the past 3 months.
Volatility Over Time: ALC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 25,000 | David Endicott | www.alcon.com |
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company’s Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery.
Alcon Inc. Fundamentals Summary
| ALC fundamental statistics | |
|---|---|
| Market cap | US$44.15b |
| Earnings (TTM) | US$1.05b |
| Revenue (TTM) | US$9.56b |
42.1x
P/E Ratio4.6x
P/S RatioIs ALC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALC income statement (TTM) | |
|---|---|
| Revenue | US$9.56b |
| Cost of Revenue | US$4.24b |
| Gross Profit | US$5.32b |
| Other Expenses | US$4.28b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | 2.12 |
| Gross Margin | 55.67% |
| Net Profit Margin | 10.96% |
| Debt/Equity Ratio | 22.5% |
How did ALC perform over the long term?
See historical performance and comparison